Luca Issi
Stock Analyst at RBC Capital
(2.07)
# 2,911
Out of 4,944 analysts
202
Total ratings
40.98%
Success rate
-8.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $21 → $17 | $8.10 | +109.88% | 10 | Aug 8, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $25 → $21 | $10.86 | +93.37% | 5 | Aug 8, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $40 → $38 | $17.80 | +113.48% | 9 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $210 → $230 | $196.02 | +17.34% | 3 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $38 → $42 | $56.60 | -25.80% | 14 | Aug 5, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $4 → $5 | $6.54 | -23.55% | 1 | Jul 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $25 → $23 | $11.64 | +97.68% | 3 | Jul 29, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.47 | +61.94% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.03 | +870.87% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $23.90 | -24.69% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $28 | $25.66 | +9.12% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $4.67 | +328.27% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $330 | $429.93 | -23.24% | 27 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $95 | $15.99 | +494.12% | 7 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.52 | +286.47% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $12.48 | +36.27% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.02 | +62.09% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $6.15 | +469.11% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $16.86 | +54.21% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $41.41 | +69.04% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $56.86 | +23.11% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.30 | +67.83% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $32.94 | +73.04% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $46.23 | +44.93% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.29 | +74.67% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $28.11 | +173.92% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $8.45 | +77.51% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.79 | +682.12% | 5 | Aug 7, 2024 |
REGENXBIO
Aug 8, 2025
Maintains: Outperform
Price Target: $21 → $17
Current: $8.10
Upside: +109.88%
Intellia Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $10.86
Upside: +93.37%
Arrowhead Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $40 → $38
Current: $17.80
Upside: +113.48%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $196.02
Upside: +17.34%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Sector Perform
Price Target: $38 → $42
Current: $56.60
Upside: -25.80%
Fulcrum Therapeutics
Jul 30, 2025
Maintains: Sector Perform
Price Target: $4 → $5
Current: $6.54
Upside: -23.55%
Dyne Therapeutics
Jul 29, 2025
Maintains: Outperform
Price Target: $25 → $23
Current: $11.64
Upside: +97.68%
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.47
Upside: +61.94%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.03
Upside: +870.87%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $23.90
Upside: -24.69%
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $25.66
Upside: +9.12%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.67
Upside: +328.27%
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $429.93
Upside: -23.24%
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $15.99
Upside: +494.12%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.52
Upside: +286.47%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $12.48
Upside: +36.27%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $8.02
Upside: +62.09%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $6.15
Upside: +469.11%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $16.86
Upside: +54.21%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $41.41
Upside: +69.04%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $56.86
Upside: +23.11%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.30
Upside: +67.83%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $32.94
Upside: +73.04%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $46.23
Upside: +44.93%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.29
Upside: +74.67%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $28.11
Upside: +173.92%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $8.45
Upside: +77.51%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.79
Upside: +682.12%